Brief: Tevogen Bio Reports Its Investigational Sars-Cov-2 Specific T Cell Therapy, Tvgn-489, Retains Activity Against The Dominant Jn.1 Variant
20/03/2024 11:03
March 20 (Reuters) - Tevogen Bio Holdings Inc TVGN.O :
* TEVOGEN BIO REPORTS ITS INVESTIGATIONAL SARS-COV-2
SPECIFIC T
CELL THERAPY, TVGN-489, RETAINS ACTIVITY AGAINST THE DOMINANT
JN.1 VARIANT
* TEVOGEN BIO: TVGN 489 RETAINS ACTIVITY AGAINST CURRENTLY
DOMINANT & HIGHLY MUTATED JN.1 STRAIN BASED ON REVIEW OF THIS
VARIANT'S PROTEIN SEQUENCES
Source text for Eikon: ID:nBw2GPR1ya
Further company coverage: TVGN.O
((Reuters.Briefs@thomsonreuters.com;))